Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-12-01 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
BLOCK LISTING INTERIM REVIEW
Foreign Filer Report
2023-12-01 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2023-12-01 English
Block listing Interim Review
Report Publication Announcement Classification · 1% confidence The document is identified by the 'RNS Number' and contains a 'BLOCK LISTING SIX MONTHLY RETURN' for the 'ASTRAZENECA PLC'. It details the balance and movement of unallotted securities under various share option plans over a specific period (1 JUNE 2023 to 30 NOVEMBER 2023). This type of filing, which reports on the status of securities reserved for employee share schemes, is a specific regulatory disclosure. While it is a regulatory filing, the structure and content strongly align with routine reporting required by listing authorities, often categorized under general regulatory announcements or specific share/capital changes. Given the options, 'Regulatory Filings (RNS)' is the most appropriate general category for a routine, non-core financial report like a Block Listing Return, especially since there isn't a specific code for 'Share Scheme Return'. It is not a 10-K, ER, or IR. It is a formal regulatory update distributed via RNS.
2023-12-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a notification released via RNS (Regulatory News Service) on December 1, 2023. It explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights (1,549,926,211) as of November 30, 2023. This content directly relates to the company's capital structure and shareholder voting rights denominator. While it contains voting rights information, it is not the declaration of the *results* of a vote (DVA), nor is it a general management change (MANG) or a director's dealing (DIRS). It is a specific regulatory disclosure concerning capital/voting rights. However, given the options, the most fitting category for a routine regulatory update concerning voting rights/capital structure that isn't a major financing event (CAP) or a director trade (DIRS) is often captured under the general regulatory announcement category, RNS, or potentially DVA if interpreted broadly. Since the core content is the calculation of the total voting rights denominator as required by transparency rules, and it is explicitly distributed via RNS, the most accurate general classification for this type of mandatory regulatory update that doesn't fit a more specific category like DIRS or DIV is RNS. If 'Voting rights and capital' were a specific code, it would fit there, but among the provided codes, RNS serves as the best fit for a mandatory, non-periodic regulatory disclosure.
2023-12-01 English
DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS
Foreign Filer Report
2023-12-01 English
Discontinuation of two CRYSTALIZE evidence trials
Legal Proceedings Report Classification · 1% confidence The document begins with 'RNS Number : 2716V' and is distributed via 'RNS, the news service of the London Stock Exchange.' It announces a specific corporate event: the discontinuation of two Phase III clinical trials (STABILIZE-CKD and DIALIZE-Outcomes) for the drug Lokelma. This is a material, non-financial operational update released through the regulatory news service. Since it is a specific announcement of corporate action/development distributed via the RNS system, and it doesn't fit neatly into categories like ER, CT, or DIRS, the most appropriate classification is the general regulatory announcement category, RNS, as per the definition of a fallback for miscellaneous filings that do not fit elsewhere, although it is a specific type of regulatory news release.
2023-12-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.